FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Secti	on 30(h)	of the	Investment	Con	npany Act o	of 1940						
Name and Address of Reporting Person* SOTO JOHN						2. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ANGO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) VP - OUS Sales				
(Last) (First) (Middle) 603 QUEENSBURY AVE.						3. Date of Earliest Transaction (Month/Day/Year) 07/27/2007												
(Street) QUEENSBURY NY 12804				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			2A. Deemed Execution Date,			Code (Instr. 5)			d (A) or	5. Amour Securitie Beneficia Owned F	nt of 6. Over the feature of 6. Over the 6. Over the feature of 6. O		: Direct I r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
			Table II -	Derivat	tive	Sec	urities	Acc	quired, Dis	spo	sed of,	or Bene	ficially	Owned				
Derivative Conversion Date Execurity or Exercise (Month/Day/Year) if a		3A. Deemed Execution D if any	3A. Deemed 4. Execution Date, Tr		ction nstr.	5. Number of		S, options, convertib 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Securiti Underlying Derivative (Instr. 3 and	d Amount ies g Security	Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				С	ode	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		,			
Non- Qualified Stock Option (right to buy)	\$17.76	07/27/2007			A		21,100		07/27/2008 ⁽¹	1) (07/27/2017	Common Stock	21,100	\$0	21,10	0	D	
Incentive Stock Option (right to buy) ⁽²⁾	\$16.84								01/29/2007	, 1	11/04/2014	Common Stock	2,583		2,583		D	
Incentive Stock Option (right to buy) ⁽²⁾	\$18.11								01/29/2007	' (09/02/2013	Common Stock	17,220		17,220		D	
Incentive Stock Option (right to buy) ⁽²⁾	\$21.71								01/29/2007	' (03/08/2016	Common Stock	2,127		2,127	7	D	
Incentive Stock Option (right to buy) ⁽²⁾	\$24.27								01/29/2007	· 1	12/02/2015	Common Stock	5,162		5,162	2	D	
Non- Qualified Stock Option (right to buy) ⁽²⁾	\$21.71								01/29/2007	, (03/08/2016	Common Stock	10,786		10,78	6	D	
Non- Qualified Stock Option (right to buy) ⁽²⁾	\$24.27								01/29/2007		12/02/2015	Common Stock	5,169		5,169	9	D	

Explanation of Responses:

- $1. \ Options \ for \ 25\% \ of \ the \ total \ number \ of \ shares \ each \ become \ exercisable \ on \ 7/27/08, \ 7/27/09, \ 7/27/10, \ and \ 7/27/11.$
- 2. Options to acquire .1722 shares of AngioDynamics common stock were received in exchange for options to acquire 1 share of RITA Medical Systems, Inc., in conjunction with AngioDynamics acquisition of RITA Medical on January 29, 2007. Upon exercise, the option holder is also entitled to \$.515 per original RITA share, or \$2.99 per AngioDynamics share exercised.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Ronald F. Lamy and Michael E. Trimarchi, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as as an officer and/or director of AngioDynamics, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of January 2007.

/s/ John Soto